These Healthcare and Bank Stocks Had Incredible Runs in 2025. Why Gains Will Continue This Year.
With a 58% gain, CVS Health had its best year since 1982—and it wasn't the only strong performer.
Fiscal Year: January - December
CVS Health Corporation (CVS), listed on the NYSE, has a market capitalization of $. As of Jan 06, 2026, the stock is trading at $80.42 per share, offering investors a clear view of its current market value. CVS Health Corporation is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 216.91, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. CVS Health Corporation also offers a dividend yield of 3.31%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that CVS Health Corporation (CVS) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for CVS Health Corporation is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for CVS Health Corporation, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for CVS Health Corporation is 16.22, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, CVS Health Corporation (CVS) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether CVS Health Corporation (CVS) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of CVS Health Corporation (CVS) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of CVS Health Corporation. To access the full SS Score, consider upgrading your subscription.
CVS Health Corporation is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of 216.91. Investors should compare these metrics with industry peers to gauge whether CVS Health Corporation is outperforming or underperforming within its sector.
With a 58% gain, CVS Health had its best year since 1982—and it wasn't the only strong performer.
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
DULUTH, Ga.--(BUSINESS WIRE)--Codoxo, the leading provider of AI and generative AI-powered healthcare payment integrity solutions, raised $35M in Series C funding, led by CVS Health Ventures. Echo Hea...
Chewy Inc. gained 12% during the quarter as the company delivered solid results driven by higher autoship subscription activity and expanding private-label offerings. The largest contributors to Fund ...
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
TipRanks' ranking service discusses three dividend-paying stocks, including Devon Energy and CVS Health.
CNBC's Jim Cramer sits down with CVS Health CEO David Joyner to discuss the company's investor day, how healthcare technology is changing, the role of artificial intelligence and more.
Unvaccinated residents can receive a measles vaccine at select CVS Pharmacy and MinuteClinic locations across the state WOONSOCKET, R.I. , Dec. 11, 2025 /PRNewswire/ -- As South Carolina public health...
CVS Health Corporation (CVS) Analyst/Investor Day Prepared Remarks Transcript
CNBC's Jim Cramer explains why he is keeping an eye on shares of CVS Health.
CVS Health's (NYSE: CVS) latest results affirm several points: their sales and adjusted profits remain stable, and they are adjusting their forecasts upward. Nonetheless, the quality of their profits ...
CVS wants investors to know it sees bigger profits ahead, and has new AI plans.
CVS Health is positioned for continued outperformance, with a strong turnaround driving industry-leading results and a reiterated "Buy" rating. CVS's Q3 showed 7.8% revenue growth, 47% adjusted EPS gr...
Famed investor Jim Cramer says he “salutes” DaviCVSd Joyner after CVS Health (NYSE: CVS) raised its profit guidance for 2026 – reinforcing the new management's turnaround plan is starting to bear frui...
CVS Health Corporation is a top S&P 500 performer in 2025, up 78% YTD, with strong operational and financial momentum. I reiterate a Buy rating for CVS, raising my intrinsic value target to $93, based...
CVS Health's stock was up about 4% at the market open on Tuesday after the company boosted its revenue and profit guidance for the year and detailed its full-year expectations for 2026.
CVS Health Inc. (NYSE: CVS) outlined its future growth plans at its investor day on Tuesday.
CNBC's Jim Cramer delivers his daily Mad Dash.
CVS Health raised its full-year outlook and guided for profit growth next year.
The healthcare company says it expects to post a narrower per-share loss in 2025.
CVS Health on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
Outlines strategy to deliver best-in-class execution, transform consumer experiences, be the partner of choice, and harness unique enterprise capabilities Updates 2025 full-year financial guidance; ...
CVS remains a great Buy here, driven by the raised FY2025 adj EPS guidance and the robust outperformance against its healthcare peers despite the industrywide headwinds. Margin recovery is expected to...
New report highlights the company's role as a top U.S. employer, investing in improving health and supporting local communities WOONSOCKET, R.I. , Dec. 5, 2025 /PRNewswire/ -- CVS Health® (NYSE: CVS) ...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2025 | 6.68B | 5.52% | Est @5.5% |
| 2026 | 7.03B | 5.24% | Analyst x3 |
| 2027 | 8.56B | 21.78% | Analyst x4 |
| 2028 | 9.66B | 12.93% | Analyst x3 |
| 2029 | 11.08B | 14.68% | Analyst x3 |
| 2030 | 11.89B | 7.34% | Est @7.3% |
| 2031 | 12.59B | 5.87% | Est @5.9% |
| 2032 | 13.20B | 4.85% | Est @4.8% |
| 2033 | 13.75B | 4.13% | Est @4.1% |
| 2034 | 14.21B | 3.38% | Est @3.4% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2023A | 10.40B | 1.00 | 10.40B |
| 2024A | 6.33B | 1.00 | 6.33B |
| 2025E | 6.68B | 1.07 | 6.22B |
| 2026E | 7.03B | 1.15 | 6.10B |
| 2027E | 8.56B | 1.24 | 6.92B |
| 2028E | 9.66B | 1.33 | 7.29B |
| 2029E | 11.08B | 1.42 | 7.79B |
| 2030E | 11.89B | 1.53 | 7.79B |
| 2031E | 12.59B | 1.64 | 7.69B |
| 2032E | 13.20B | 1.76 | 7.51B |
| 2033E | 13.75B | 1.89 | 7.29B |
| 2034E | 14.21B | 2.02 | 7.02B |
| Terminal | 303.32B | 2.02 | 149.91B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.